Carboplatin is a Viable Option in Treating Patients with Completely Resected Non-Small Cell Lung Cancer

A new study suggests that carboplatin offers a higher tolerability measured by discontinuation rates than cisplatin, and that there was no significant difference in recurrence rates. In this MEDtalk, Vivi Quoc Nguyen from Odense University Hospital presents the results of this study that compared patients who had received cisplatin and vinorelbine to those who had received carboplatin and vinorelbine.